Literature DB >> 23337891

Phacomatosis pigmentokeratotica is caused by a postzygotic HRAS mutation in a multipotent progenitor cell.

Leopold Groesser1, Eva Herschberger, Ana Sagrera, Tor Shwayder, Katharina Flux, Laura Ehmann, Andreas Wollenberg, Antonio Torrelo, Lorea Bagazgoitia, Blanca Diaz-Ley, Sigrid Tinschert, Ilske Oschlies, Sebastian Singer, Marion Mickler, Agusti Toll, Michael Landthaler, Francisco X Real, Christian Hafner.   

Abstract

Phacomatosis pigmentokeratotica (PPK) is a rare epidermal nevus syndrome characterized by the co-occurrence of a sebaceous nevus and a speckled lentiginous nevus. The coexistence of an epidermal and a melanocytic nevus has been explained by two homozygous recessive mutations, according to the twin spot hypothesis, of which PPK has become a putative paradigm in humans. However, the underlying gene mutations remained unknown. Multiple tissues of six patients with PPK were analyzed for the presence of RAS, FGFR3, PIK3CA, and BRAF mutations using SNaPshot assays and Sanger sequencing. We identified a heterozygous HRAS c.37G>C (p.Gly13Arg) mutation in four patients and a heterozygous HRAS c.182A>G (p.Gln61Arg) mutation in two patients. In each case, the mutations were present in both the sebaceous and the melanocytic nevus. In the latter lesion, melanocytes were identified to carry the HRAS mutation. Analysis of various nonlesional tissues showed a wild-type sequence of HRAS, consistent with mosaicism. Our data provide no genetic evidence for the previously proposed twin spot hypothesis. In contrast, PPK is best explained by a postzygotic-activating HRAS mutation in a multipotent progenitor cell that gives rise to both a sebaceous and a melanocytic nevus. Therefore, PPK is a mosaic RASopathy.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23337891     DOI: 10.1038/jid.2013.24

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  29 in total

Review 1.  Somatic mosaicism: on the road to cancer.

Authors:  Luis C Fernández; Miguel Torres; Francisco X Real
Journal:  Nat Rev Cancer       Date:  2015-12-18       Impact factor: 60.716

2.  Activating HRAS mutation in nevus spilus.

Authors:  Kavita Y Sarin; Jennifer M McNiff; Shirley Kwok; Jinah Kim; Paul A Khavari
Journal:  J Invest Dermatol       Date:  2014-01-03       Impact factor: 8.551

3.  Photoletter to the editor: A neurocutaneous rarity: phacomatosis pigmentokeratotica.

Authors:  Thiago Cardoso Vale; David Márcio Barbosa Santos; Ricardo Oliveira Maciel; Francisco Cardoso; Rudolf Happle
Journal:  J Dermatol Case Rep       Date:  2014-06-30

4.  [Nevus spilus: An example of mosaic RASopathy].

Authors:  C Hafner
Journal:  Hautarzt       Date:  2015-05       Impact factor: 0.751

5.  Many mosaic mutations.

Authors:  W D Foulkes; F X Real
Journal:  Curr Oncol       Date:  2013-04       Impact factor: 3.677

Review 6.  Mosaicism in Cutaneous Disorders.

Authors:  Young H Lim; Zoe Moscato; Keith A Choate
Journal:  Annu Rev Genet       Date:  2017-11-27       Impact factor: 16.830

7.  RAS mutations in benign epithelial tumors associated with BRAF inhibitor treatment of melanoma.

Authors:  Jessica C Hassel; Leopold Groesser; Eva Herschberger; Wilko Weichert; Christian Hafner
Journal:  J Invest Dermatol       Date:  2014-07-18       Impact factor: 8.551

8.  Epidermal, sebaceous, and melanocytic nevoid proliferations are spectrums of mosaic RASopathies.

Authors:  Su Luo; Hensin Tsao
Journal:  J Invest Dermatol       Date:  2014-10       Impact factor: 8.551

9.  Phenotypic expansion of POFUT1 loss of function mutations in a disorder featuring segmental dyspigmentation with eczematous and folliculo-centric lesions.

Authors:  Lihi Atzmony; Theodore D Zaki; Richard J Antaya; Keith A Choate
Journal:  Am J Med Genet A       Date:  2019-09-30       Impact factor: 2.802

Review 10.  Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.

Authors:  Young H Lim; Diana Ovejero; Kristina M Derrick; Michael T Collins; Keith A Choate
Journal:  J Am Acad Dermatol       Date:  2016-08       Impact factor: 11.527

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.